pelareorep
Biologicalexperimental
Pelareorep is a proprietary isolate of the unmodified human reovirus being developed as a systemically administered immuno-oncological viral agent for the treatment of solid tumors and hematological malignancies. Pelareorep is an oncolytic virus, which means that it preferentially lyses cancer cells. Pelareorep also promotes an inflamed tumor phenotype through innate and adaptive immune responses. Preliminary clinical trials indicate that it may have anti-cancer effects across a variety of cancer types when administered alone and in combination with other cancer therapies. — Wikipedia
Clinical trial activity
7 trials · 17 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Mar 29, 2019 (NCT04102618)
Timeline
Indications
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPelareorep ↗
- ChEMBLCHEMBL3545069 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05514990 | Phase 1/Phase 2 (Phase 2) | Oct 7, 2022 | National Cancer Institute (NCI), University of Southern California |
| NCT07280377 | Phase 1/Phase 2 (Phase 2) | Oct 27, 2021 | AIO-Studien-gGmbH, Crolll Gmbh, Oncolytics Biotech |
| NCT05519059 | Phase 1 | Oct 11, 2021 | Adlai Nortye Biopharma Co., Ltd., Jinlin University |
| NCT04445844 | Phase 2 | Jul 13, 2020 | Incyte, National Cancer Institute (NCI), Oncolytics Biotech, Rutgers University |
| NCT04215146 | Phase 2 | Mar 31, 2020 | Oncolytics Biotech, PrECOG, LLC. |
| NCT03605719 | Phase 1 | Jul 1, 2019 | Bristol-Myers Squibb, City of Hope National Medical Center, Emory University, National Cancer Institute (NCI), National Institutes of Health (NIH), Oncolytics Biotech, Phylogeny, University of Utah |
| NCT04102618 | Early Phase 1 (Phase 1) | Mar 29, 2019 | Oncolytics Biotech, SOLTI Breast Cancer Research Group |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (17)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Oncolytics Biotech | For profit | 5 | 3 | 2 | 2019 |
| National Cancer Institute (NCI) | Government | 3 | 0 | 2 | 2019 |
| Adlai Nortye Biopharma Co., Ltd. | For profit | 1 | 1 | 1 | 2021 |
| AIO-Studien-gGmbH | For profit | 1 | 0 | 1 | 2021 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2019 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Crolll Gmbh | For profit | 1 | 0 | 1 | 2021 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Incyte | For profit | 1 | 0 | 1 | 2020 |
| Jinlin University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2019 |
| Phylogeny | For profit | 1 | 0 | 1 | 2019 |
| PrECOG, LLC. | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Rutgers University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| SOLTI Breast Cancer Research Group | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Southern California | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Utah | Academic/Hospital | 1 | 0 | 1 | 2019 |
17 organizations
Page 1 / 1